NCT05005247View on ClinicalTrials.gov

Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

August 5, 2022

Study Completion Date

August 5, 2022

Conditions
Group B Streptococcus Infection
Interventions
BIOLOGICAL

GBS-NN/NN2

GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

Trial Locations (1)

CF48 4DR

Simbec Clinical Pharmacology, Merthyr Tydfil

Sponsors

Lead Sponsor

Minervax ApS
All Listed Sponsors
lead

Minervax ApS

OTHER

NCT05005247 - Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine | Biotech Hunter | Biotech Hunter